Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Bas Thijssen"'
Autor:
Marit A. C. Vermunt, Debbie G. J. Robbrecht, Lot A. Devriese, Julie M. Janssen, Bas Thijssen, Marianne Keessen, Maarten vanEijk, Rob Kessels, Ferry A. L. M. Eskens, Jos H. Beijnen, Niven Mehra, Andries M. Bergman
Publikováno v:
Cancer Reports, Vol 4, Iss 4, Pp n/a-n/a (2021)
Abstract Background ModraDoc006 is an oral formulation of docetaxel, which is co‐administered with the cytochrome P450 3A4 and P‐glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase
Externí odkaz:
https://doaj.org/article/ad84cb565b37425dadb093bae9e81fac
Autor:
Laura Molenaar-Kuijsten, Milan van Meekeren, Remy B. Verheijen, Judith V. M. G. Bovée, Marta Fiocco, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Aisha B. Miah, Hans Gelderblom, Rick L. M. Haas, Neeltje Steeghs
Publikováno v:
Cancers, Vol 13, Iss 22, p 5780 (2021)
There is a lack of understanding whether plasma levels of anticancer drugs (such as pazopanib) correlate with intra-tumoral levels and whether the plasma compartment is the best surrogate for pharmacokinetic and pharmacodynamic evaluation. Therefore,
Externí odkaz:
https://doaj.org/article/c3f1d4b3365f4a8dad8a15b3f5a71773
Autor:
Ignace C. Roseboom, Bas Thijssen, Hilde Rosing, Fabiana Alves, Brima M. Younis, Ahmed M. Musa, Jos H. Beijnen, Thomas P.C. Dorlo
Bioanalytical assay development and validation procedures were performed to quantify antiprotozoal drug paromomycin in human skin tissue by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. Paromomycin, an aminoglycosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d56bca18e9087ff86d22d603b072076
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-493792
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-493792
Autor:
Frans L. Opdam, Robin M. J. M. van Geel, Neeltje Steeghs, Emilie M.J. van Brummelen, Alwin D. R. Huitema, Serena Marchetti, Jos H. Beijnen, Jan H.M. Schellens, Sanne Huijberts, Hilde Rosing, Kim Monkhorst, Saskia M. Pulleman, Bas Thijssen, René Bernards
Publikováno v:
Cancer Chemotherapy and Pharmacology, 85(5), 917-930. Springer Verlag
Purpose KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo.
Autor:
Bas Thijssen, Hans Gelderblom, Milan van Meekeren, Aisha Miah, Rick L. Haas, Laura Molenaar-Kuijsten, Judith V.M.G. Bovée, Alwin D. R. Huitema, Neeltje Steeghs, Hilde Rosing, Marta Fiocco, Remy B. Verheijen
Publikováno v:
Cancers
Volume 13
Issue 22
Cancers, Vol 13, Iss 5780, p 5780 (2021)
Volume 13
Issue 22
Cancers, Vol 13, Iss 5780, p 5780 (2021)
There is a lack of understanding whether plasma levels of anticancer drugs (such as pazopanib) correlate with intra-tumoral levels and whether the plasma compartment is the best surrogate for pharmacokinetic and pharmacodynamic evaluation. Therefore,
Autor:
Marianne Keessen, Debbie Robbrecht, Rob Kessels, Marit A C Vermunt, Bas Thijssen, Niven Mehra, Ferry A.L.M. Eskens, Andries M. Bergman, Lot A. Devriese, Julie M Janssen, Maarten van Eijk, Jos H. Beijnen
Publikováno v:
Cancer Reports, Vol 4, Iss 4, Pp n/a-n/a (2021)
Cancer Reports, 4(4):e1367. Wiley-Blackwell Publishing Ltd
Cancer Reports
Cancer Reports, 4(4):e1367. Wiley-Blackwell Publishing Ltd
Cancer Reports
BACKGROUND: ModraDoc006 is an oral formulation of docetaxel, which is co-administered with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase I trials in
Autor:
Ignace C. Roseboom, Hilde Rosing, Dinesh Mondal, Marcel B. M. Teunissen, Bas Thijssen, Fabiana Alves, Thomas P. C. Dorlo, Jos H. Beijnen
Publikováno v:
Journal of pharmaceutical and biomedical analysis, 207:114402. Elsevier
Miltefosine is the only oral drug approved for the treatment of various clinical presentations of the neglected parasitic disease leishmaniasis. In cutaneous leishmaniasis and post-kala-azar dermal leishmaniasis, Leishmania parasites reside and multi
Autor:
Alwin D. R. Huitema, Stefanie L. Groenland, Jos H. Beijnen, Niels de Vries, Bas Thijssen, Hilde Rosing, Ruben A G van Eerden, Stijn L.W. Koolen, Remy B. Verheijen, Ron H.J. Mathijssen, Neeltje Steeghs
Publikováno v:
Clinical Pharmacokinetics, 59(7), 941-948. Adis
Clinical Pharmacokinetics, 59(7), 941. Adis International Ltd
Clinical Pharmacokinetics, 59(7), 941. Adis International Ltd
Background and Objective: Pazopanib is an oral tyrosine kinase inhibitor used in the treatment of renal cell carcinoma and soft-tissue sarcoma. At the approved dose of 800 mg once daily (QD), 16–20% of patients are being underdosed and at risk of d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8523041abf904f0a19949668d37b9b9e
https://pure.eur.nl/en/publications/31c7fb36-4788-426f-8676-2c471695966c
https://pure.eur.nl/en/publications/31c7fb36-4788-426f-8676-2c471695966c
Autor:
Filip De Vos, Ferry A.L.M. Eskens, Martijn P. Lolkema, Bas Thijssen, Robin van Geel, Neeltje Steeghs, Emilie M.J. van Brummelen, Serena Marchetti, Lot A. Devriese, René Bernards, Frans L. Opdam, Alwin D. R. Huitema, Hilde Rosing, Jan H.M. Schellens, Kim Monkhorst, Jos H. Beijnen, Sanne Huijberts
Publikováno v:
British Journal of Cancer, 122(8), 1166. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer, 122(8), 1166-1174. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer, 122(8), 1166-1174. Nature Publishing Group
Background Mutations in KRAS result in a constitutively activated MAPK pathway. In KRAS-mutant tumours existing treatment options, e.g. MEK inhibition, have limited efficacy due to resistance through feedback activation of epidermal growth factor rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93b187e3733cbb74ac196b6f9e85915e
https://dspace.library.uu.nl/handle/1874/411157
https://dspace.library.uu.nl/handle/1874/411157
Autor:
Bas Thijssen, Serena Marchetti, J. H. M. Schellens, Jacobus A. Burgers, M. van Nuland, Alwin D. R. Huitema, Hilde Rosing, Jos H. Beijnen
Publikováno v:
Clinical pharmacology in drug developmentReferences. 9(8)
Microdose studies are exploratory trials to determine early drug pharmacokinetics in humans. In this trial we examined whether the pharmacokinetics of gemcitabine at a therapeutic dose could be predicted from the pharmacokinetics of a microdose. In t